Compare Recursion Pharmaceuticals Inc (RXRX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Health Care Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 20.3× Recursion Pharmaceuticals Inc's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| RXRX | XLV | |
|---|---|---|
Market Cap | $2.14B | $43.48B |
Volume | 30,789,535 | 11,121,431 |
Sector | Health | — |
52-Week High | $6.79 | $175.68 |
52-Week Low | $2.84 | $141.95 |
Typical Hold Time | 23 Days | 100 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
XLV trades at $170.81, up 1.18% with a bearish technical signal from moving averages. The ETF's low 0.08% expense ratio and healthcare sector diversification provide defensive positioning amid market volatility. Recent options activity shows increased put volume, indicating some investor caution despite healthcare's traditional defensive characteristics during economic uncertainty.
Healthcare sector ETFs like XLV offer defensive exposure with potential upside from demographic trends and innovation. Key risks include political volatility around healthcare policy and concentration in large-cap US stocks. The ETF's cost efficiency and sector positioning make it attractive for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
